Pharma Firms Told To ‘Keep Your Distance’ When Patients Come To EU CHMP Meetings
Executive Summary
The European Medicines Agency is planning to expand the involvement of patients in benefit-risk evaluation of medicines following a successful pilot, but one EU patient group has advised drug companies not to contact patients during their visits to the agency as this could lower the value of their input.
You may also be interested in...
EMA Shifts Gear On Patient Feedback During Drug Review
The European Medicines Agency is exploring the feasibility and utility of contacting patients’ organizations for their input as soon as its medicines evaluation committee starts reviewing a new drug.
EMA Brings Non-EU Regulators Into CHMP Meetings
The European Medicines Agency is continuing with its plans to involve non-EU regulators in scientific reviews. It notes in its 2016 activity report that Israeli regulators for the first time took part in a CHMP meeting.
EMA Needs More Cases To Assess Value Of Involving Patients In CHMP Meetings
The European Medicines Agency is extending an ongoing pilot project in which it invites patients to take part in certain meetings that its human medicines committee, the CHMP, holds to discuss the benefits and risks of drugs.